Country
Clinical Trials in Iceland
Studies with at least one site in Iceland. Open a trial for its sites in Iceland, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 34Symptomatic Hypertrophic Cardiomyopathy (HCM)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
- Trial name
- FOREST-HCM (NCT04848506)
- Testing
- Aficamten (5 - 20 mg)
- Where
- 141 sites in United States, Argentina and 17 more
- Volunteers
- 900 people
- Sponsor
- Cytokinetics
Intensive Care Patients, Intensive Care Unit Patients
The Intensive Care Platform Trial
Among critically ill patients, many die, and many of the survivors and their family members struggle for years with reduced quality of life. Critically ill patients are treated in intensive care units (ICUs).
- Conditions
- Intensive Care Patients, Intensive Care Unit Patients, Critical Illness
- Trial name
- INCEPT (NCT06667999)
- Testing
- Albumin, No albumin use, LMWH in weight-adjusted dose
- Where
- 40 sites in Austria, Denmark and 5 more
- Volunteers
- 10,000 people
- Sponsor
- Anders Perner
Cervical Cancer Screening, Cervical Cancer
Culturally Adapted Materials to Increase Cervical Cancer Screening Among Polish Women in Iceland
This study tests whether sending Polish women residing in Iceland a culturally adapted invitation letter - tailored in language and messaging to the target group - increases participation in cervical cancer screening compared…
- Conditions
- Cervical Cancer Screening, Cervical Cancer, Cervical Cancer (Early Detection)
- Trial name
- NCT07856862
- Testing
- Culturally adapted cervical cancer screening invitation letter, Standard cervical cancer screening invitation letter
- Where
- Iceland
- Volunteers
- 2,000 people
- Sponsor
- The Primary Health Care in the Capital Area
Obsessive-Compulsive Disorder (OCD)
OCD Summer Treatment Program for Adolescents in Iceland
The aim of the study is to examine the effectiveness of OCD treatment delivered in a group format for adolescents during a two week intensive summer treatment program.
- Trial name
- OCDtreatment (NCT07465354)
- Testing
- Intensive cognitive-behavioral treatment with exposure / response prevention
- Where
- Iceland
- Volunteers
- 70 people
- Sponsor
- University of Iceland
Respiratory Infections
Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.
The purpose of this study is to investigate whether fish oil containing free fatty acids affects people's susceptibility to viral infections such as colds, influenza, and COVID-19, as well as the course of these illnesses.
- Trial name
- OmegaCold FFA (NCT07314593)
- Testing
- Omega-3 oil with 2% Free Fatty Acids, Vegatable oil
- Where
- Iceland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Landspitali University Hospital
Attention-Deficit/Hyperactivity Disorder (ADHD)
The ADHD Kids´ Study for Children 9-12 Years of Age
The aim of the study is to compare the efficacy of The OutSMARTers program- an ADHD skills training group program for children aged 9-12 to customized individual counseling provided by a professional, The Kid Counseling Program.
- Trial name
- OutSmarters (NCT07379359)
- Testing
- The OutSMARTers Program, The Kid Counseling Program
- Where
- Iceland
- Volunteers
- 100 people
- Sponsor
- University of Iceland
Arrhythmia, Bradycardia
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival…
- Conditions
- Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
- Trial name
- PPR (NCT00271180)
- Testing
- Device
- Where
- 333 sites in United States, Australia and 33 more
- Volunteers
- 20,000 people
- Sponsor
- Medtronic
Leukemia, Acute Lymphoblastic
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive…
- Trial name
- NCT03911128
- Testing
- Observational
- Where
- 57 sites in Denmark, Estonia and 6 more
- Volunteers
- 500 people
- Sponsor
- Mats Heyman
Leukemia, Acute Lymphoblastic
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system…
- Trial name
- NCT04307576
- Testing
- Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy
- Where
- 137 sites in Belgium, Denmark and 13 more
- Volunteers
- 6,430 people
- Sponsor
- Mats Heyman
Hyperoxaluria, Cystinuria
Prospective Research Rare Kidney Stones (ProRKS)
The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase…
- Conditions
- Hyperoxaluria, Cystinuria, Dent Disease, Lowe Syndrome
- Trial name
- ProRKS (NCT02780297)
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Completed, with results posted
All –Hidradenitis Suppurativa
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with…
- Trial name
- NCT03827798
- Testing
- CFZ533, LYS006, MAS825
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Early Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype.
- Trial name
- APOLLOE4 (NCT04770220)
- Testing
- Experimental: ALZ-801
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Alzheon Inc.
Coronary Heart Disease (CHD)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a…
- Trial name
- VESALIUS-CV (NCT03872401)
- Testing
- Evolocumab
- Where
- 852 sites in United States, Argentina and 31 more
- Volunteers
- 12,301 people
- Sponsor
- Amgen
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
- Trial name
- NCT04270760
- Testing
- Olpasiran
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 281 people
- Sponsor
- Amgen